MTT #110: Peptides, politics & the perils of medicine without evidence
About this episode
The episode discusses the implications of an FDA advisory committee's recommendation on experimental peptides and various current healthcare issues.
In this week’s episode of Medicine: The Truth , hosts Jeremy Corr and Dr. Robert Pearl go in search of the facts beneath healthcare’s biggest headlines. Today’s show opens with one of the hottest and least understood medical topics: experimental peptides . Pearl explains that an FDA advisory committee narrowly recommended allowing compounding pharmacies to provide six experimental peptides to patients. This is not the same as traditional FDA approval. Rather than reviewing a drug through the usual three-phase clinical trial process, the recommendation would allow suppliers to provide peptide ingredients that compounding pharmacies could use to fill prescriptions. Pearl then explains why this distinction matters. If the FDA follows the committee’s recommendation, many patients may assume the peptides have been vetted like other approved medications. He warns that this could leave the nation in a medical gray zone, with broad access but little rigorous evidence on safety, effectiveness, dosing or long-term risk. The episode then turns to several follow-up stories and new medical developments, including the cyclospora outbreak, CDC leadership, pediatric e-bike injuries, AI-designed…
More episodes of Fixing Healthcare Podcast
- FHC #227: Dr. Rod Rohrich on social media, science and AI-powered care
- FHC #226: Peptides, primary care & the false choices in American medicine
- FHC #225: Kindness, burnout and the limits of medical leadership
- FHC #224: Austin Chiang on burnout, misinformation and the future of med-tech
- FHC #223: How GenAI & World Cup strategy can help fix healthcare
- MTT #109: Healthcare affordability, GLP-1s and the patient revolt ahead
Explore listener stats, chart rankings, contacts and more on the Fixing Healthcare Podcast podcast page.